A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination With External Radiotherapy in Stage IIB, III and IV NSCLC.
Phase of Trial: Phase I/II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors YM BioSciences
- 30 May 2011 Status changed from recruiting to discontinued.
- 11 Feb 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
- 26 Jan 2010 YM Biosciences receives FDA clearance to extend this trial into USA.